Antidiabetic potency of glimepiride and naringin: an and investigation.

Glimepiride (GLM) is one of the potential antidiabetic drugs used in clinics for a long time. It is currently used in combination with metformin along with other drugs, but has shown various complications in patients from long-term use. Thus, the hypothesis is to use a lower dose of GLM with a non-toxic class of flavonoid, naringin (NARN), for better therapy with minimal side-effects.

A Mechanism-based Perspective on the Use of Flavonoids in the Treatment of Diabetes and its Complications.

Diabetes is a chronic, irreversible, non-infectious metabolic syndrome associated with low insulin production by the pancreas or due to insulin resistance. The management landscape for diabetes is swiftly evolving due to ongoing advancements. Conventional treatment approaches have struggled to fully address the root causes of the disease while also carrying significant risks of adverse effects.

Distinct patient characteristics are associated with clinical presentation and prognosis in thromboangiitis obliterans.

Thromboangiitis obliterans (TAO) is a rare but threatening disease associated with significant morbidity and mortality. The pathophysiology is poorly understood, the diagnosis is often obscure and causal treatment options are limited. In the current study, we aimed to identify distinct TAO patient clusters that differed in clinical presentation and prognosis.